Caleb Overpeck, MD
Family Medicine · Daleville, INNPI 1740576529
Payments from drug & device makers
Across 488 payments — averaging $12.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$870
- Amgen$665
- AbbVie$635
- Lilly USA, LLC$550
- Pfizer$398
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,224100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 62 | $1,036 |
| GSK | 96 | $870 |
| Amgen(2 entities) | 44 | $665 |
| AbbVie(2 entities) | 69 | $635 |
| Lilly USA, LLC | 46 | $550 |
| Pfizer | 23 | $398 |
| Novo Nordisk | 27 | $357 |
| Boehringer Ingelheim | 19 | $260 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $232 |
| Amarin Pharma, Inc. | 12 | $209 |
| Merck | 17 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $137 |
| Sanofi-aventis U.S. LLC | 6 | $90 |
| Kowa Pharmaceuticals America, Inc. | 6 | $80 |
| Arbor Pharmaceuticals, Inc. | 1 | $70 |
| Johnson & Johnson(2 entities) | 4 | $61 |
| Otsuka America Pharmaceutical, Inc. | 4 | $60 |
| Biohaven Pharmaceuticals, Inc. | 4 | $51 |
| Daiichi Sankyo Inc. | 3 | $47 |
| Astellas Pharma US Inc | 3 | $47 |
| Exact Sciences | 2 | $34 |
| Nevro Corp. | 1 | $28 |
| Edwards Lifesciences | 1 | $27 |
| Ironwood Pharmaceuticals, Inc | 2 | $23 |
| Boston Scientific | 1 | $21 |
| Mylan Specialty L.p. | 1 | $15 |
| Circassia Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| IBSA Pharma Inc. | 1 | $12 |
| Nestle Healthcare Nutrition Inc. | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
How this compares
$6,233 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 147 | $187,264 |
| OzempicSemaglutide | 121 | $133,750 |
| JardianceEmpagliflozin | 88 | $100,248 |
| FarxigaDapagliflozin Propanediol | 104 | $96,199 |
| EliquisApixaban | 95 | $89,216 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $81,328 |
| TrulicityDulaglutide | 36 | $55,258 |
| LinzessLinaclotide | 95 | $51,198 |
| VraylarCariprazine Hcl | 19 | $29,282 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $23,539 |
| JanuviaSitagliptin Phosphate | 23 | $22,157 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $20,411 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $17,014 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $16,954 |
| MyrbetriqMirabegron | 22 | $15,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $550 | $242,523183 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix, Breo Ellipta, Arexvy | $870 | $134,312223 claims |
| Novo NordiskOzempic | $357 | $133,750121 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,036 | $122,463159 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $260 | $107,657102 claims |
| PfizerEliquis, Abrysvo, Premarin | $398 | $96,592122 claims |
| AbbVieLinzess, Vraylar | $635 | $80,480114 claims |
| MerckJanuvia, Janumet | $165 | $39,11139 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $15,59122 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $232 | $9,75311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Daleville
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.